Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China.

• First report of the complete shift from ptxP1 to ptxP3 in a large city in China. • Genomic analysis of a novel erythromycin-resistant ptxP3 Bordetella pertussis clone in China. • First report of PRN-deficient B. pertussis isolates in China. • Proof of the circulation of the same B. pertussis clone among households. The number of cases of pertussis has been increasing since 2014 in China, with high prevalence of macrolide resistance in ptxP1 isolates and low prevalence in ptxP3 isolates. This study aimed to investigate the dynamic changes in the B. pertussis population from paediatric patients and household contacts in Shanghai between 2018 and 2022. Clinical data of laboratory-confirmed cases of pertussis were analysed, while isolates recovered from hospitalized children and household contacts were characterized by antimicrobial susceptibility testing, whole-genome sequencing, vaccine antigen gene typing and phylogenetical analysis. Among 640 laboratory-confirmed cases, 340 (53.1%) were fully vaccinated with DTaP and 114 (17.8%) were hospitalized for treatment. The frequency of erythromycin resistance in the 103 B. pertussis isolates from inpatients (n =73) and household contacts (n =30) was 78.6% (81/103), increasing from 65% (13/20) in 2018 to 100% (26/26) in 2022. The proportion of ptxP3 isolates increased from 35% (7/20) in 2018 to 100% (26/26) in 2022. Based on genomic analysis, a novel ptxP3 clone (MT28-Shanghai) belonging to sublineage IVd was discovered and dominated in 2021–2022, which was characterized with ptxP3 , erythromycin resistance and prn 150. Twelve (11.7%) predicted pertactin-deficient isolates were found; of these, nine were ptxP3 isolates and three were ptxP1 isolates. A complete shift from ptxP1 to ptxP3 in Shanghai, China, which may have been accelerated by the domination of a novel erythromycin-resistant MT28 clone, challenges the pertussis vaccines used at present in China. [ABSTRACT FROM AUTHOR]